Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies

Table 1 Amplification efficiencies of individual gene assays in the Onco type DX Prostate Cancer Assay reporting the GPS

Gene Assay	Estimated Amplification Efficiency	Lower 95% CI	Upper 95% CI
ARF1	93.9	92.8	95.0
ATP5E	90.2	88.2	92.2
AZGP1	88.1	86.5	89.7
BGN	92.5	90.5	94.7
CLTC	97.2	95.9	98.6
COL1A1	95.4	94.5	96.3
FAM13C1	88.5	85.8	91.3
FLNC	96.9	94.9	99.0
GPS1	94.4	92.4	96.6
GSN	91.5	89.7	93.4
GSTM2	95.9	93.8	98.2
KLK2	92.4	91.7	93.1
PGK1	89.9	88.4	91.4
SFRP4	93.9	91.2	96.7
SRD5A2	98.7	96.3	101.4
TPM2	100.2	98.8	101.8
TPX2	98.9	97.1	100.7

Estimated amplification efficiencies and 95% confidence intervals for the 17 genes comprising the GPS derived from a 15-point dilution series.

ISSN: 1471-2164